Formulation Featured Articles

  1. Advancing Formulation Strategies for Complex Drug Products 4/30/2026

    An event-focused overview examining how formulation development and stability strategies support robust, scalable drug products discussed at the DDF Summit Berlin.

  2. Strengthening Drug Product CMC through Drug Product Science | AAPS 4/27/2026

    At AAPS, drug product experts discuss how formulation, stability, and analytical services enable robust CMC strategies, reduce development risk, and support confident regulatory decision‑making.

  3. Managing CMC Risk For Complex Peptide And Nucleic Acid Therapeutics 4/24/2026

    At TIDES USA 2026, experts discuss how formulation science, stability strategies, and advanced analytics help reduce CMC risk and enable confident development of peptide and nucleic acid therapeutics.

  4. Expanding The IV → SC Framework: What Reformulation Really Means 4/22/2026

    IV → SC is a system design challenge. Success depends on aligning formulation, device, manufacturing, and clinical strategy early to avoid costly failures and redesigns.

  5. How To Select The Right Platform For Your Vaccine Production Process 4/16/2026

    Evaluate surface treatments, scalability, and contamination risks to select the right adherent platform. Testing early ensures a seamless transition from benchtop to production.

  6. High Potency APIs And The Evolving Demands Of Drug Development 4/13/2026

    See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

  7. Drug-Device Combination Products: 4 Evolving Platforms For 2026 4/10/2026

    Biologic advantage won’t come from better biology alone, but from delivery technology and designing the full experience around patients, providers, and supply chains.

  8. Integrate Upstream/Downstream To Reduce Development Risks And Costs 4/8/2026

    Coordinating unit operations can help reduce costs and mitigate challenges in process development. Check out these key takeaways from the Bioprocess Online Live event “Optimizing Process Development Through Upstream and Downstream Integration.”

  9. From IV To Subcutaneous: It's Not About Convenience, It's About System Design 4/6/2026

    IV→SC transition extends beyond dose, volume, concentration, and device; it requires integrated system design, not a series of isolated optimizations.

  10. Evaluating Mass Spectrometry Methods For Host Cell Protein Quantification 3/26/2026

    New USP 1132.1 guidelines standardize mass spectrometry for host cell protein analysis. These methods provide the specific protein identification and quantification needed to reduce clinical risk.